aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Solu Therapeutics, founded by Longwood Fund and based in Boston, Massachusetts, is a precision-medicine company focused on developing therapeutics to eliminate cells that drive oncologic, inflammatory, and autoimmune diseases. The company leverages its proprietary CyTaC (Cytotoxicity Targeting Chimera) platform and drug candidates, licensed from GSK, to target antibody-intractable cell surface markers. Solu Therapeutics aims to revolutionize treatment paradigms in cancer, immunology, and autoimmunity through innovative, targeted therapies.
Notable figures affiliated with Solu Therapeutics include key scientists and industry experts from Longwood Fund and GSK. The company has achieved significant milestones in advancing its CyTaC platform, positioning itself as a leader in precision medicine. By focusing on unmet medical needs and leveraging cutting-edge technology, Solu Therapeutics has made a substantial impact on the therapeutic landscape, offering new hope for patients with challenging diseases.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Therapeutics
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Solu Therapeutics founded?
Solu Therapeutics was founded in 2022.
Where is Solu Therapeutics’s headquarters located?
Solu Therapeutics’s headquarters is located in Boston, MA, US.
When was Solu Therapeutics’s last funding round?
Solu Therapeutics’s most recent funding round was for $31M (USD) in August 2023.
How many employees does Solu Therapeutics have?
Solu Therapeutics has 11 employees as of Feb 4, 2024.
How much has Solu Therapeutics raised to-date?
As of July 05, 2023, Solu Therapeutics has raised a total of $31M (USD) since Aug 1, 2023.
Add Comparison
Total Raised to Date
$31M
USD
Last Update Aug 1, 2023
Last Deal Details
$31M
USD
Aug 1, 2023
Seed
Total Employees Over Time
11
As of Feb 2024
Solu Therapeutics Address
Boston,
Massachusetts
02110
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts